A randomized phase 2 network trial of tivantinib plus cetuximab versus cetuximab in patients with recurrent/metastatic head and neck squamous cell carcinoma
Journal article published in 2020 by
Sara E. Kochanny 
,
Francis P. Worden,
Douglas R. Adkins,
Dean W. Lim,
Julie E. Bauman ,
Stephanie A. Wagner,
Ryan J. Brisson ,
Theodore G. Karrison,
Walter M. Stadler ,
Everett E. Vokes ,
Tanguy Y. Seiwert
,
Francis P. Worden,
Douglas R. Adkins,
Dean W. Lim,
Julie E. Bauman ,
Stephanie A. Wagner,
Ryan J. Brisson ,
Theodore G. Karrison,
Walter M. Stadler ,
Everett E. Vokes ,
Tanguy Y. Seiwert
This paper is made freely available by the publisher.
Full text: Download
Published version:
archiving forbidden
Data provided by 